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1 Contributed equally to this work.Recent studies have shown microRNA-21 (miR-21) is overexpressed in several types of cancer and
contributes to tumor resistance to chemotherapy. In this study, we investigated whether miR-21
mediated resistance of the leukaemia cell line K562 to the chemotherapeutic agent daunorubicin
(DNR). miR-21 expression was upregulated in the DNR resistant cell line K562/DNR compared to
its parental line K562. Stable transfection of miR-21 induced drug resistance in K562, while suppres-
sion of miR-21 in K562/DNR led to enhanced DNR cytotoxicity. Additional experiments indicate that
the mechanism of miR-21 drug resistance involves the PI3K/Akt pathway and changes following
PTEN protein expression. This study provides a novel mechanism for understanding leukaemia drug
resistance.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction has been shown to function in the oncogenesis and drug resistanceDaunorubicin (DNR) is a chemotherapeutic that belongs to the
anthracycline family and is used to treat cancer [1,2]. Since it
was developed as a clinical application for treating leukaemia, dau-
norubicin-based chemotherapy has become one of the most effec-
tive anti-cancer drugs [3,4]. However, as with other chemotherapy
agents, drug resistance to DNR continues to be a major clinical
obstacle for the successful treatment of leukaemia, thus limiting
its clinical use [5]. Drug resistance is considered to be a multifacto-
rial phenomenon that involves several major mechanisms, such as
increased DNA damage repair, reduced apoptosis, changes in drug
metabolism, and increased energy-dependent drug efﬂux, as well
as changes in glutathione transferase and topoisomerase II expres-
sion [6,7]. Unfortunately, the speciﬁc mechanisms involved in leu-
kaemia DNR drug resistance remain largely unknown.
MicroRNAs (miRNAs) are small, non-codingRNAs that negatively
regulate the expression of target genes post-transcriptionally by
binding to the 30UTR of mRNA [8]. Dysregulation of microRNAs has
been reported in a variety of human cancers [9]. Increasing evidence
indicates that microRNAs play a role in tumor cell resistance and/or
sensitivity to chemotherapeutic agents [10]. In particular, miR-21chemical Societies. Published by E[11], however the role of thismicroRNA in the leukaemia DNR resis-
tance has not been described. In this work, we show that miR-21 is
highly expressed in DNR resistant leukaemia K562 cell line. Addi-
tional experiments suggest miR-21 contributes resistance to DNR
by regulating PTEN expression in K562 cells. Our ﬁndings indicate
that upregulation of miR-21 and subsequent downregulation of
PTEN is a novel mechanism for DNR resistance in leukaemia.2. Materials and methods
2.1. Cell culture
The K562 cell line and the K562/DNR-resistant cell line were a
kind gift from Dr. Su Liping (Shanghai Ruijin Hospital). The cells
were cultured in RPMI 1640 medium (GIBCO) supplemented with
10% fetal bovine serum, 100 g/ml L-glutamine, 100 units/ml peni-
cillin, and 100 lg/ml streptomycin. The HEK293T cells were grown
in DMEM that contained 10% fetal bovine serum, 100 g/ml L-gluta-
mine, 100 units/ml penicillin, and 100 lg/ml streptomycin.
2.2. Retroviral transduction of miR-21 and transfection of miR-21 ASO
A 300 bp DNA fragment containing the miR-21 precursor was
PCR ampliﬁed from human genomic DNA (Roche Applied science)lsevier B.V. All rights reserved.
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CCAGAAATGC-30 and reverse: 50- CTCGAGCCACCAGACAGAAGGACC
AGAGT-30; the XhoI and BglII recognition sites are underlined. The
amplicon was cloned into a modiﬁed MSCV-PGK-GFP vector (Clo-
tech). To generate a cell line that stably expressed miR-21 (K562-
MSCV miR-21), 10 lg expression vector or empty vector with
10 lg packing plasmid (gag/pol and VSVG) was incubated with Fu-
gene 6 (Roche) for 15 min at room temperature and subsequently
added to the HEK293T cells. The viral supernatant was harvested
after 48 h, and the cells were treated by a spin infection with ret-
roviral supernatant (1 ml supernatant per 1  106 cells plus polyb-
rene) in 6-well plates that were pre-coated with retronectine
(Takara); after 24 h, the cells were centrifuged at 1500g for
30 min. The GFP positive cells were approximately 50–70% and
sorted by ﬂow cytometry. Control oligonucleotides and miR-21
complementary oligonucleotides were purchased from Invitrogen
(Carlsbad, CA). The sequences were as follows: miR-21 antisense
oligonucleotide (ASO), 50-TCAACATCAGTCTGATAAGCTA-30 and
control ASO, 50-GTGGATATTGTTGCCATCA-30. The cells were
transfected with Lipofectamine 2000 according to the manufac-
turer’s instructions (Invitrogen). The oligonucleotides were used
at a ﬁnal concentration of 200 nM in antibiotic-free Opti-MEM
medium (Invitrogen). All of the assays were performed 48 h after
transfection.
2.3. Cell viability assay
Cells were seeded into 96-well plates in RPMI-1640 medium
containing 10% FBS. After 24 h, the cells were treated with serial
dilutions of DNR. Approximately 72 h after DNR treatment, MTT
was added to a ﬁnal concentration of 0.5 mg/ml, and the cells were
incubated for 4 h at 37 C. The optical density was read at 570 nm
with a microplate spectrophotometer. Each experiment was car-
ried out in triplicate and repeated three times.
2.4. MicroRNA array
Total RNA samples were analyzed by CapitalBio (Beijing, China)
for miRNA microarray experiments .The chips contain 743 probes
in triplicate, corresponding to 576 human (including 122 predicted
miRNAs), 358mouse, and 238 ratmiRNAs (based on SangermiRNAs
databasemiRBase8.2). Experimental procedureswere performed as
described in detail on thewebsite of CapitalBio http://www.capital-
bio.com. Brieﬂy, total RNAwas isolated using themiRNeasy kit (Qia-
gen). MicroRNA labeling, hybridization and washing were carried
out following manufacturer’s instructions. Double-channel laser
scanner LuxScan10 K/A (CapitalBio)wasused for ﬂuorescence scan-
ning, and the image signalswere transformed todigital signals using
image analysis software LuxScan3.0 (CapitalBio). Differentially ex-
pressed miRNAs were identiﬁed by the Signiﬁcance Analysis of
Microarrays (SAM, version 3.0, from Stanford University).
2.5. Real-time PCR
The total cellular RNA was isolated with a RecoverAll kit (Ambi-
on Inc., Austin, Texas) for both the miR-21 and PTEN-mRNA analy-
ses according to the manufacturer’s instructions. To detect miR-21
expression, a TaqMan microRNA Assay (Applied Biosystems, Foster
City, CA) was performed as described [12] on an Applied Biosys-
tems ABI 7500 Real Time PCR system. U6 was used as a control.
To detect PTEN-mRNA expression, real-time PCR was performed
with a Quantitect SYBR Green PCR Kit (Qiagen). b-Actin was used
to normalize the PTEN-mRNA expression level. The forward and re-
verse primers sequences used for PTEN mRNA ampliﬁcation were
50-GAGGGATAAA ACACCATG-30 and 50-AGGGGTAGGATGTGAAC-
CAGTA-30, respectively. The b-actin forward and reverse primerswere 50-CAGAGCCTCGCCTTTGCC-30 and 50-GTCGCCCACATAGG
AATC-30, respectively. All of the real-time PCR assays were
performed in triplicate.
2.6. Northern blot analysis
Northern blots were performed as described previously [13].
Brieﬂy, 15 lg of total RNA was separated on a 15% denaturing poly-
acrylamide gel, transferred to GeneScreen Plus membranes (Perk-
inElmer, Waltham, Mass). The membranes were hybridized at
37 C for 24 h to c-32P labelled probe. The probe was end-labelled
with [c-32P]ATP (6000 Ci/mmol) and T4 Polynucleotide Kinase. The
miR-21 probe sequence was 50-TCAACATCAGTCTGATAAGCTA-30,
and the U6 probe sequence was 50-GCAGGGGCCATGCTAAT
CTTCTCTGTATCG-30.
2.7. Luciferase assay
A PTEN 30 UTR luciferase reporter was created by inserting full
length human PTEN 30 UTR into the XhoI and NotI sites in the psi-
CHECK2 vector (Promega) downstream from the renilla luciferase
coding sequence. The PTEN 30UTR was PCR ampliﬁed from human
genomic DNA with the following primers: forward, 50-TCGCTCGA-
GATTTTTTTTTATCAAGAGGG-30 and reverse, 50-TCGGCGGCCGCGA-
CAAGAATGAGACTTTAATC-30. Mutations within the putative miR-
21 binding sites were created with a QuikChange site-directed
mutagenesis kit (Stratagene, La Jolla, CA). The mutagenic primers
were forward, 50-ACTTGTGGCAACAGTTTACTTTGCAGTTG-30 and re-
verse, 50-CAACTGCAAAGTAAACTGTTGCCACAAGT-30. The K562
cells were plated in 96-well plates at 5000 cells per well the day
before transfection. Transfection was performed in triplicate with
FuGENE6 (Roche) and 100 ng of the plasmid mixture (90 ng of
the miR-21expression vector and 10 ng of the reporter vector).
Luciferase assays for both ﬁreﬂy and renilla luciferase were per-
formed 48 h after transfection with a Dual-Glo Luciferase assay
kit (Promega). Luminescence was quantiﬁed using a Tecan Spectra-
ﬂuor Plus machine. The renilla luciferase readings were normalized
to the ﬁreﬂy luciferase activity in the corresponding well.
2.8. Western blot
The cells were washed twice with PBS that contained 1 mM
phenyl-methylsulphonyl ﬂuoride and then lysed in Lysis Reagent
(Sigma–Aldrich, St. Louis, MO). Cell lysates (approximately 30 lg
of protein) were loaded on an 8% SDS–PAGE gel and subsequently
transferred to a polyvinylidene diﬂuoride membrane (PVDF; Bio-
rad). The membranes were blocked with 5% milk and incubated
with primary antibody overnight at 4 C, followed by incubation
with secondary antibody. The primary antibodies for PTEN, p-Akt,
and Akt were purchased from Cell Signaling Technology, the
b-actin antibody was purchased from Sigma and the PDCD4
antibody was purchased from Abcam Ltd. Band detection via en-
zyme-linked chemiluminescence was performed according to the
manufacturer’s protocol (ECL; Pierce Biotechnology Inc., Rockford,
IL). The protein bands were quantiﬁed using ImageJ 1.33 software
(NIH), and the data were normalized to b-actin.
2.9. siRNA transfection
A SignalSilence PTEN siRNA kit was purchased from Cell Sig-
naling Technology (CST), and the transfection was performed
according to the manufacturer’s protocol. The cells were prepared
for further analysis 48 h after transfection. The transfection efﬁ-
ciency was evaluated by ﬂuorescence microscopy by calculating
the percentage of ﬂuorescein–labelled cells. The transfection efﬁ-
ciency was approximately 70%.
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The data are presented as the mean ± S.E. Statistical analysis
was performed with SPSS 13.0 software. One-way ANOVA with
post hoc Tukey’s test was performed for experiments that involved
more than two groups, while Student’s t-test was performed for
comparisons between two groups. A P < 0.05 was considered to
be signiﬁcant.
3. Results
3.1. miR-21 is upregulated in the DNR-resistant K562/DNR cell line
Our primary miRNA proﬁling studies indicated that 3 microR-
NAs were upregulated (miR-21, miR-125b, and miR-99a) and 9
microRNAs were downregulated (miR-23a, miR-29a, mir-29c,
miR-30b, miR-30c, miR-183, miR-221, miR-222, and miR-224) by
at least 1.5 fold in the K562/DNR-resistant cells compared to the
parental K562 cells. We selected miR-21 to further validate the ar-
ray results because previous studies have shown that miR-21 is an
oncogene that is related to drug resistance [10,11]. Therefore, we
ﬁrst veriﬁed differences in miR-21 expression by northern blot
(Fig. 1A) and real-time PCR analyses (Fig. 1B). The quantitative
PCR results showed that the miR-21 expression level was higher
in the K562/DNR cells than in the K562 cells (Fig. 1A, ⁄⁄⁄P < 0.001),
indicating that miR-21 may be associated with DNR resistance in
K562 cells.
3.2. Overexpression of miR-21 renders the K562 cells resistant to DNR
To directly test the relationship between miR-21 and chemore-
sistance in the K562 cells, we further studied the DNR-resistant
K562 cell line. The survival curves of the K562/DNR cells and the0
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Fig. 1. miR-21 expression in K562 and K562/DNR cells. (A) A northern blot showing
miR-21 expression in K562 and K562/DNR cells; U6 (small nuclear RNA U6) was
used as an internal control. (B) The relative miR-21 expression levels were
examined by real-time PCR. The error bar indicates the S.E. ⁄⁄⁄P < 0.001.parental K562 cell line are shown in Fig. 2A. The K562 cells were
stably transduced with an MSCV-miR-21 vector or empty vector
and treated with various doses of DNR. Overexpression of miR-21
was associated with signiﬁcantly increased survival of the K562
cells (Fig. 2B). At DNR concentrations higher than 0.01 lM, the
K562 cells that were transduced with miR-21 had a signiﬁcantly
higher survival than the control group (⁄P < 0.05). This result sug-
gests that miR-21 contributes to DNR resistance in the K562 cells.
3.3. Knockdown of miR-21 partially sensitizes the K562/DNR cells to
DNR
We further investigated the effects of miR-21 on DNR-induced
cytotoxicity in K562/DNR cells that were transfected with a miR-
21 ASO. The cells were transfected with either the miR-21 ASO
or a control ASO and were subsequently incubated with various
doses of DNR. As is shown in Fig. 2C, the miR-21 ASO effectively re-
duced the expression of miR-21 (⁄⁄⁄P < 0.001). At DNR concentra-
tions greater than 0.1 lM, K562 cells that were transfected with
the miR-21 ASO had a signiﬁcantly lower survival than the control
group (Fig. 2D. ⁄P < 0.05), suggesting that decreasing miR-21
expression alters DNR sensitivity in K562/DNR cells.
3.4. Overexpression of miR-21 activates the PI3K/Akt pathway by
downregulating PTEN
Although the PTEN 30UTR is not a perfect match to the seed se-
quence of miR-21 because there was a G:U pair (Fig. 3A), a previous
study showed that PTEN is a miR-21 target in cholangiocarcinoma
cell lines [14]. We thus hypothesized that PTEN is a direct miR-21
target in K562 cells. To conﬁrm this, the K562 cells were co-trans-
fected with PTEN-30UTR luciferase reporter and miR-21. Transfec-
tions with control vector were performed in parallel. As is shown
in Fig. 3B, miR-21 markedly decreased the activity of the PTEN-
UTR reporter (⁄⁄P < 0.01). However, transfection of the PTEN-30UTR
mutant did not affect reporter activity (#P > 0.05). We also as-
sessed whether miR-21 regulated PTEN expression in K562 cells.
Overexpression of miR-21 decreased the PTEN protein level
(⁄⁄⁄P < 0.001) in K562 cells, whereas knockdown of miR-21 by
ASO-miR-21 increased the PTEN protein level (⁄⁄⁄P < 0.001) in
K562/DNR cells (Fig. 3C and E); however, no changes were seen
in PTEN mRNA expression (Fig. 3D, #P > 0.05). Because PTEN is a
negative regulator of the PI3K/Akt pathway, we hypothesised that
overexpression of miR-21 may activate PI3K/Akt by reducing the
PTEN protein level, resulting in K562 resistance to DNR. As is
shown in Fig. 3F, K562 cells that were transduced with miR-21
have increased Akt phosphorylation (⁄⁄⁄P < 0.001); additionally,
knockdown of miR-21 in the K562/DNR resistant cell line de-
creased Akt phosphorylation (⁄⁄⁄P < 0.001). These results show that
PTEN is a target of miR-21, and that overexpression of miR-21 acti-
vates the PI3K/Akt pathway by decreasing the PTEN protein level.
Recent studies have also shown that anti-miR-21 treatment sensi-
tises K562 cells to arsenic trioxide by suppressing PDCD4 expres-
sion [15–17]. To explore the role of PDCD4 in DNR-induced
resistance in K562 cells, we examined PDCD4 protein levels in
K562 and K562/DNR cells. Overexpression of miR-21 in the K562
cells or knockdown of miR-21 in the K562/DNR cells did not
change the PDCD4 protein levels(#P > 0.05), suggesting that
PDCD4 is not involved in DNR drug resistance in this cell line.
3.5. PTEN is a key signal molecule in induced K562 DNR resistance
Previous studies have shown that PTEN is involved in drug
resistance in several types of cancer [18,19]; however, its role in
DNR sensitivity in the K562 cell line remains unclear. To explore
the relationship between PTEN and DNR-induced cytotoxicity, we
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Fig. 2. miR-21 confers DNR resistance in K562 cells. (A) A survival curve of drug-resistant K562/DNR cells and K562 parental cells. Cell viability was determined using an MTT
assay. (B) The K562 cells were transduced with an MSCV-miR-21 vector or an empty vector and were subsequently treated with various doses of DNR. Cell viability was
determined using an MTT assay. The error bar shows the S.E. for three independent experiments. (C) K562/DNR cells were transfected with ASO-miR-21 or a control ASO.
miR-21 expression was quantiﬁed by real-time PCR. (D) K562/DNR cells were transfected with ASO-miR-21 vector, a control ASO, or vehicle and were subsequently treated
with various doses of DNR. Cell viability was determined using an MTT assay. The error bar shows the S.E. for three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01, and
⁄⁄⁄P < 0.001.
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lowed by treatment with various doses of DNR. PTEN siRNA effec-
tively reduced the PTEN protein level (Fig. 4A). Furthermore, K562
cells that were pre-treated with PTEN siRNA had increased survival
compared to the control group (Fig. 4C). More importantly, the
K562 cells that were treated with PTEN siRNA had increased pAkt
levels (Fig. 4B) and a survival pattern that is similar to cells with
miR-21 overexpression, suggesting that miR-21 confers DNR resis-
tance via regulating PTEN in the K562 cells.
4. Discussion
In this paper, for the ﬁrst time, we show that DNR-induced drug
resistance is associated with upregulation of miR-21 in the leukae-
mia cell line K562. miR-21 may regulate the survival of leukaemia
cell lines by targeting PTEN expression and causing subsequent
changes in the PI3K/Akt pathway.
Several studies have shown that miR-21 is an oncogenic miRNA
that is overexpressed in various types of cancer, such as breast
[20], pancreatic endocrine [21], pre-B-cell lymphoma [22], glio-
blastoma [23] and prostate cancer [24]. Recent studies have indi-
cated that miR-21 contributes to drug resistance in solid tumours
through several pathways [21,25–27]. In the present study, we
found that miR-21 was upregulated in K562/DNR cells comparedto K562 cells, indicating that miR-21 is involved in leukaemia
DNR drug resistance. Additional studies involving over and under-
expression of miR-21 were performed to conﬁrm the effect of
miR-21 on DNR resistance in K562 cells. Our studies show that
overexpression of miR-21 attenuates cell death, whereas knock-
down of miR-21 promotes cell death.
Numerous miR-21 targets have been identiﬁed, including
PDCD4 [28], MARCKS [29], LRRFIP1 [27], TGFBR2 [30], and TPM1
[31]. Meng et al. [14,32] ﬁrst veriﬁed that PTEN is a direct target
of miR-21 and showed that this microRNA plays a role in human
cholangiocarcinoma cell lines and human hepatocellular cancer.
Of these miR-21 targets, we focused on the phosphatase and tensin
homolog deleted on chromosome 10 (PTEN), because it is an
important gene that is involved in leukaemia pathology [33,34]
and drug resistance [35,36]. Studies have shown that transfection
of PTEN in the drug-resistant AML cell line (HL60AR) or ALL cell
line (EU21) causes chemosensitivity to anti-cancer agents
[35,36]. Consistent with this ﬁnding, we demonstrate here that
PTEN is a target of miR-21 and that it plays a role in DNR resistance
in the K562 cell line. Moreover, knockdown of PTEN signiﬁcantly
increased cell survival and had an overall effect that was similar
to miR-21 overexpression. To our knowledge, this is the ﬁrst time
anyone has described an association between miR-21, PTEN
expression and drug resistance in DNR-treated K562 cells.
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406 H. Bai et al. / FEBS Letters 585 (2011) 402–408Moreover, PTEN is a negative regulator of the PI3K/Akt pathway.
Consequently, we saw that overexpression of miR-21 or knock-down of PTEN activated Akt kinase. Akt regulates cell growth and
inhibits apoptosis via controlling downstream proteins [34].
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H. Bai et al. / FEBS Letters 585 (2011) 402–408 407Several lines of evidence have shown that Akt phosphorylates GSK-
3b [37], Foxo3a [38], mTOR [39] and Bcl-2 [40] in K562 cells and
thus regulates cell growth. Further experiments are required to
validate the direct downstream targets of Akt that are responsible
for this mechanism of drug resistance.
In this study, we found that a miR-21 ASO cannot completely
sensitize the K562/DNR cells. This suggests that upregulation of
miR-21 is not the only mechanism responsible for DNR resistance.
It may be that other microRNAs targeting PTEN are involved in
DNR resistance in the leukaemia cell line. Recent studies revealed
that PTEN is regulated by multiple microRNAs including miR-17-
92 cluster [41], miR-26a [42], miR-216a/217 cluster [43], miR-
214 [44], miR-221/222 [45], miR-486 [46] and miR-22 [47]. As is
shown in our microRNA array results, miR-221 and miR-222 are
differentially expressed in K562 and K562/DNR cells; these
microRNAs may contribute to DNR resistance through targeting
PTEN. In addition, microRNAs may target other apoptosis related
proteins and involve in DNR resistance. miR-125b, which was
upregulated in K562/DNR cells, has been shown to suppress the
pro-apoptotic protein BAK1, thus inhibiting apoptosis [48]. An-
other study suggested that miR-221 and miR-222 down regulate
c-kit and inhibit erythroleukaemic cell growth [49]. Future studies
are needed to assess the role of these microRNAs in DNR resistance.
Previous studies have shown that a miR-21 ASO can modulate
the chemosensitivity of K562 cells to arsenic trioxide through
downregulation of PDCD4 protein expression [15–17]. However,
our data did not indicate that PDCD4 plays a role in DNR resistance
in K562 cells. This discrepancy suggests that miR-21 may regulate
different targets in response to different drugs. Additionally, the
miR-21 expression level may differ in these cell lines.
In summary, our results show that leukaemia cells with ele-
vated miR-21 expression and decreased PTEN protein expressionwere more resistant to DNR than the control cells. These results
may help with the development of personalized treatment for pa-
tients who have abnormal levels of miR-21 or PTEN. Furthermore,
this novel miR-21/PTEN/PI3K/Akt signalling pathway in leukaemia
cells may provide drug targets for the sensitisation of tumour cells
and could be applied to treat chemotherapy resistance in leukae-
mia patients. Future investigations using patient samples are
needed to further support the function of miR-21 in leukaemia
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